CN Patent

CN121868312A — 用氘代jak抑制剂治疗脱毛障碍

Assigned to Sun Pharmaceutical Industry Co ltd · Expires 2026-04-17 · 0y expired

What this patent protects

本披露是治疗受试者的脱毛障碍的方法，该脱毛障碍有益地通过给予JAK1和/或JAK2抑制剂治疗。该方法包括给予该受试者约4 mg至约50 mg的范围的量的化合物 (I)或其药学上可接受的盐。本发明还提供包含化合物 (I) 的组合物以及此类组合物在所述方法中的用途。化合物 (I)

USPTO Abstract

本披露是治疗受试者的脱毛障碍的方法，该脱毛障碍有益地通过给予JAK1和/或JAK2抑制剂治疗。该方法包括给予该受试者约4 mg至约50 mg的范围的量的化合物 (I)或其药学上可接受的盐。本发明还提供包含化合物 (I) 的组合物以及此类组合物在所述方法中的用途。化合物 (I)

Drugs covered by this patent

deuruxolitinib-phosphate (DEURUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: CN121868312A
Jurisdiction: CN
Classification: —
Expires: 2026-04-17
Drug substance claim: No
Drug product claim: No
Assignee: Sun Pharmaceutical Industry Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.